An Information Technology Architecture for Drug Effectiveness Reporting and Post-Marketing Surveillance

International Journal of Healthcare Information Systems and Informatics (IJHISI)

Volumn 2, Issue 3, 2007, Pages 65-80

  Gupta, Amar ^a   Woosley, Ray ^b   Crk, Igor ^a   Sarnikar, Surendra ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b Critical Path Institute   (United States)

^c DAKOTA STATE UNIVERSITY   (United States)

Author keywords

adverse event reporting; community pharmacy safety network; postmarketing surveillance

Indexed keywords

EID: 85001608958     PISSN: 15553396     EISSN: 1555340X     Source Type: Journal    
DOI: 10.4018/jhisi.2007070106     Document Type: Article

References (31)

1. Anderson, J.G., Jay, S.J., Anderson, M., & Hunt, T.J. (2002). Evaluating the capability of information technology to prevent adverse drug events: A computer simulation approach. Journal of American Medical Informatics Association, 9, 479–490.
2. Barach, P., & Small, S. (2000). Reporting and preventing medical mishaps: Lessons from non-medical near miss reporting systems. British Medical Journal, 320, 759–763.
3. Bates, D.W., Cohen, M., Leape, L.L. et al. (2001). Reducing the frequency of errors in medicine using information technology. Journal of American Medical Informatics Association, 8, 299–308.
4. Bates, D.W., Evans, R.S., Murff, H., Stetson, P.D., Pizziferri, L., & Hripcsak, G. (2003). Detecting adverse events using information technology. Journal of American Medical Informatics Association, 10, 115–128.
5. Brewer, T., & Colditz, G.A. (1999). Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs. Journal of the American Medical Association, 281, 824–829.
6. Center for Drug Evaluation and Research. Adverse event reporting system. Retrieved March 15, 2007, from http://www.fda.gov/cder/aers/de-fault.htm.
7. Classen, D.C., Pestotnik, S.L., Evans, R.S., & Burke, J.P. (1991). Computerized surveillance of adverse drug events in hospital patients. Journal American Medical Association, 266, 2847–2851.
8. Cohen, M.M., Kimmel, N.L., et al. (2005). Medication safety program reduces adverse drug events in a community hospital. Qual Saf Health Care, 14, 169–174.
9. The Critical Path Institute. (2005, Spring). C-Path Newsletter.
10. Evans, R., Pestotnik, S., & Classen, D. et al. (1992). Prevention of adverse drug events through computerized surveillance. In Proceedings of the Annu Symposium Comput Appl Med Care (pp. 437–441).
11. Farris, K.B., Kumbera, P., Halterman, T., & Fang, G. (2002). Outcomes-based pharmacist reimbursement: Reimbursing pharmacists for cognitive services. J Managed Care Pharm., 8(5), 383–393.
12. Fisher, S., & Bryant, S.G. (1990). Postmarketing surveillance: Accuracy of patient drug attribution judgments. Clin Pharmacol Ther, 48, 102–107.
13. Fisher, S., & Bryant, S.G. (1992). Postmarketing surveillance of adverse drug reactions: Patient self-monitoring. J Am Board Fam Pract, 5, 17–25.
14. Fisher, S., Bryant, S.G., & Kent, T.A. (1993). Postmarketing surveillance by patient self-monitoring: Trazodone versus fuoxetine. J Clin Psychopharmacol, 13, 235–242.
15. Fisher, S., Bryant, S.G., Kent, T.A., & Davis, J.E. (1994). Patient drug attributions and postmar-keting surveillance. Pharmacotherapy, 14, 202–209.
16. Fisher, S., Bryant, S.G., Solovitz, B.L., & Kluge, R.M. (1987). Patient-initiated postmarketing surveillance: A validation study. J Clin Pharmacol, 27, 843–854.
17. Fisher, S., Kent, T.A., & Bryant, S.G. (1995). Post-marketing surveillance by patient self-monitoring: Preliminary data for sertraline versus fuoxetine. J Clin Psychiatry, 56, 288–296.
18. Fontanarosa, P., Rennie, D., & DeAngelis, C. (2004). Postmarketing surveillance: Lack of vigilance, lack of trust. Journal of American Medical Association, 292(21).
19. Food and Drug Administration. (1996, October). The clinical impact of adverse event reporting.
20. Gandhi, T.K., Burstin, H.R., Cook, E.F., Puopolo, A.L., Haas, J.S., Brennan, T.A., & Bates, D.W. (2000). Drug complications in outpatients. Journal of General Internal Medicine, 15(3), 207–208.
21. Gandhi, T.K., Weingart, S.N., Borus, J., Seger, A.C., Peterson, J., Burdick, E. et al. (2003). Adverse drug events in ambulatory care. New England Journal of Medicine, 348(16),1556–1564.
22. Honigman, B., Lee, J., Rothschild, J., Light, P. et al. (2001). Using computerized data to identify adverse drug events in outpatients. Journal of American Medical Informatics Association, 8, 254–266.
23. Johnson, J.A., & Bootman, J.L. (1995). Drug-related morbidity and mortality. A cost-of-illness model. Archives of Internal Medicine, 155(18), 1949–1956.
24. Lazarou, J., Pomeranz, B., & Corey, P. (1998). Incidence of adverse drug reactions in hospitalized patients. Journal of American Medical Association, 279, 1200–1205.
25. Menachemi, N., Burke, D., & Brooks, R.G. (2004). Adoption factors associated with patient safety-related information technology. J Healthc Qual., 26(6), 39–44.
26. Murff, H.J., Patel, V.L., Hripcsak, G., & Bates, D.W. (2003). Detecting adverse events for patient safety research: A review of current methodologies. Journal of Biomedical Informatics, 36(1–2), 131–143.
27. Murray, M.D., Loos, B., Tu, W., Eckert, G.J., Zhou, X.H., & Tierney, W.M. (1998). Effects of computer-based prescribing on pharmacist work patterns. Journal of American Medical Informatics Association, 5(6), 585–586.
28. Oh, Y., McCombs, J.S., Cheng, R.A., & Johnson, K.A. (2002). Pharmacist time required for counseling in an outpatient pharmacy. American Journal of Health-System Pharmacy, 59(23), 2346–2355.
29. Schommer, J.C., Pedersen, C.A., Doucette, W.R., Gaither, C.A., & Mott, D.A. (2002). Community pharmacists' work activities in the United States during 2000. Journal of American Pharmacists Association, 42(3), 399–406.
30. U.S. Department of Health and Human Services. (1999, May). Managing the risk from medical product use, creating a risk management framework. Taskforce on Risk Management Report.
31. Weinberger, M., Murray, M.D., Marrero, D.G., Brewer, N., Lykens, M., Harris, L.E. et al. (2002, August). Issues in conducting randomized controlled trials of health services research interventions in nonacademic practice settings: The case of retail pharmacies. Health Services Research.